What are you searching for…

COVID-19 still remains central to scientific discoveries across the globe, here at Baker, our mission in #SupportingScience continues.


1. AstraZeneca & The University of Oxford Vaccine


In the UK, the University of Oxford’s vaccine candidate could be rolled out as early as the end of this year. The experimental vaccine, (AZD1222) which has been licensed by AstraZeneca produced an immune response in early-stage clinical trials within all evaluated participants. Once the vaccine has passed late stage clinical trials, they will be able to move forward further.

Source

2. IQVIA clinical research


IQVIA have recently revealed how COVID-19 has acted as a catalyst for trial evolution. IQVIA believe that there is now a greater need for flexibility, use of remote monitoring, data management and other solutions in order to aid the clinical research industry.

Source

3. Worldwide Statistics


To date, there have been a total of 16,889,588 COVID-19 cases recorded worldwide. Since 1951, Baker have been helping to advance science, discovery and clinical care in all areas of the globe and have continued to support science throughout the COVID-19 pandemic, including those highly skilled and dedicated individuals behind every COVID-19 test result.

Source

4. Vaccine candidate front runners


A trio of distinguished experts have revealed that there are currently four front runners when it comes to the discovery of a COVID-19 vaccine. Vaccine candidates from AstraZeneca & Oxford University (AZD1222), Moderna (mRNA-1273), Pfizer & BioNTech (BNT162b1) and CanSino (Ad5-nCoV) currently all have varying degrees of promise following their Phase I/II studies.

Source

5. New portable, rapid antigen test


Baker’s partner, Becton, Dickinson & Company have recently launched a new portable, rapid antigen test. The test has been developed to detect SARS-CoV-2 in as little as 15 minutes. Becton, Dickinson & Company have already begun shipping their new tests and are due to ramp up their manufacturing capacity to 2 million tests per week by the end of September.

The launch of this test will dramatically expand access to COVID-19 testing.

Source

Stay Connected


Make sure you join us in #SupportingScience across all of our social media channels!

Follow us on Facebook, Twitter, Instagram and LinkedIn.

Sources


1. https://uk.reuters.com/article/uk-health-coronavirus-oxford-vaccine-gil/oxford-covid-19-vaccine-developer-cautious-on-2020-roll-out-idUKKCN24M0OL, 2.https://www.outsourcing-pharma.com/Article/2020/07/20/Tech-can-help-trials-adapt-to-COVID-19-Iqvia, 3. https://www.statista.com/statistics/1043366/novel-coronavirus-2019ncov-cases-worldwide-by-country/, 4. https://www.genengnews.com/gen-edge/quartet-of-covid-19-vaccine-candidates-head-toward-the-homestretch/, 5. https://news.bd.com/2020-07-06-BD-Launches-Portable-Rapid-Point-of-Care-Antigen-Test-to-Detect-SARS-CoV-2-in-15-minutes-Dramatically-Expanding-Access-to-COVID-19-Testing